Additonal Enrolling Trials
BI-1378-0041: participants with type 2 diabetes, hypertension and established cardiovascular
Individuals who have established cardiovascular disease along with type 2 diabetes and high blood pressure may qualify for a study aiming to prevent future major cardiovascular events and to prevent the development of heart failure. Participants who qualify will be compensated after every completed visit, and all study supplies are provided at no cost to you.
ALN-AGT: Patients with Hypertension Not Adequately Controlled
Adults with high blood pressure that is not adequately controlled, who also have established cardiovascular disease or who are at risk for developing cardiovascular disease, may qualify for a study for an additional therapy that aims to prevent future major cardiovascular events and hospitalizations for heart failure while reducing hypertension. Participants who qualify will be compensated after every completed visit, and all study supplies are provided at no cost to you.
Novartis- Lp(a) ADD-Vantage: ardiovascular disease (ASCVD), and elevated LDL-C and Lp(a)
Novartis- Lp(a) ADD-Vantage: ardiovascular disease (ASCVD), and elevated LDL-C and Lp(a)
Individuals who have established cardiovascular disease and have elevated Lp(a) and LDL-C levels may qualify for a study aiming to reduce risk for future major cardiovascular events by lowering Lp(a) levels in addition to LDL-C levels. Participants who qualify will be compensated after every completed visit, and all study supplies are provided at no cost to you. We will test for Lp(a) value for those who are unsure if they have that. Lp(a) is a genetic marker, not widely tested, that is a risk factor for increased cardiovascular disease.
New Amsterdam- Rubens Treatment for those with GeFH or Cardiovascular disease
Ardylex- TEN-03-301: Treatment of Chronic Idiopathic Constipation (CIC) in Adults
Novartis- Lp(a) ADD-Vantage: ardiovascular disease (ASCVD), and elevated LDL-C and Lp(a)
This study is for those who have HeFH (Heterozygous familial hypercholesterolemia or history of CV/ASCVD (cardiovascular disease) on Lipid-lowering medication who require additional medication to lower LDL. Participants must have Type 2 diabetes and or metabolic syndrome. Compensation may be available for those who qualify for the study after meeting additional qualifying criteria.
Ardylex- TEN-03-301: Treatment of Chronic Idiopathic Constipation (CIC) in Adults
Ardylex- TEN-03-301: Treatment of Chronic Idiopathic Constipation (CIC) in Adults
Ardylex- TEN-03-301: Treatment of Chronic Idiopathic Constipation (CIC) in Adults
Adults experiencing symptoms of constipation may qualify for a study aiming to treat chronic idiopathic constipation (CIC) or functional constipation. Participants who qualify will be compensated after every completed visit, and all study supplies are provided at no cost to you.
Common trials for our site that you may see in the future
Ardylex- TEN-03-301: Treatment of Chronic Idiopathic Constipation (CIC) in Adults
Ardylex- TEN-03-301: Treatment of Chronic Idiopathic Constipation (CIC) in Adults
We do often have trials on Asthma, COPD, Arthritis, UTI, Vaccine, Type 2 diabetes, Lp(a), Chronic Kidney Disease, and many more.